RB homepage

CT Scan

 In 2020 alone, there were more than 2 million 18F-FDG PET/CT scans conducted in the United States.

mergers and acquisitions M&A partnerships

Transparent Imaging currently distributes work to more than 200 radiologists, who collectively read over 1 million imaging exams per year.

court judge gavel business man bankruptcy lawsuit

Univabs took The Radiology Group to court in May after an independent arbitrator ruled TRG owed the India-based imaging firm the six-figure sum, which it refused to pay. 

Gillian Battino, MD

Democrat Gillian Battino, MD, officially announced her bid in Wisconsin’s 29th District after previously running for a U.S. Senate spot in 2021. 

breast cancer month ribbon

Founded in 2020 by Mass General’s Constance Lehman, MD, PhD, Clairity offers the first AI tool to predict five-year breast cancer risk from routine mammograms. 

Medical societies including the American College of Radiology and Society of Interventional Radiology recently announced their support for H.R. 4002. 

Innovation at work

Six years ago, two radiologists with dissimilar backgrounds and divergent clinical interests put their heads together and launched a new practice. One physician was an academic subspecialized in musculoskeletal reads. The other, a private practitioner, concentrated on oncologic imaging. That’s how Transparent Imaging was born, powered by Konica Minolta. 

Sponsored by Konica Minolta

In a private dining room in Miami, something unusual is happening. Leaders from competing imaging centers are openly discussing their best practices—even sharing vendor recommendations and operational strategies that have doubled their volumes while cutting costs in half.

In cooperation with AbbaDox

Around the web

A growing number of private insurers are now covering these advanced technologies. Roosha Parikh, MD, told Cardiovascular Business that the hard work of SCCT and other groups has helped make this happen. 

Customers are urged to stop using these devices right away.

Researchers used AI-enabled software developed by Cleerly to evaluate the CCTA results of more than 6,000 patients. The software was consistently effective, identifying patients who may face an increased risk of poor outcomes.